AUCATZYL - Autolus Therapeutics' autologous CD19 CAR-T therapy for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia - booked its first quarter with both a positive gross margin and the volume scale to keep that margin improving from here. Net product revenue of $45.7 million in the second quarter of 2026 was up 119% from $20.9 million a year earlier, up roughly 74% sequentially from the $26.2 million reported for the first quarter, and the quarter ran at a 55% gross margin versus negative margins in every prior quarter of 2025 and just 6% in the first quarter of 2026. The combination is the cleanest evidence yet that the launch has crossed from "compelling single-payer clinical data" into "a real product with operating leverage," and it is the central reason management raised full-year 2026 product revenue guidance to $140-150 million from $120-135 million on the same morning. The single number the market is wrong about, in TickerFile's read, is how much the company's funding posture has already changed: the $75 million first tranche of the new five-year, interest-only credit facility from Perceptive Advisors, signed July 30 and disclosed in the 8-K and the subsequent events note that accompanied the second quarter 10-Q, materially extends the cash runway into the second quarter of 2028 before any milestones on the back-end $150 million of contingent tranches. The open question for the next six months is whether the second half of 2026 delivers the kind of patient throughput and gross-margin continuation that would justify the $100-150 million in milestone-tranche capital Perceptive has agreed to make available.